Back to search

Article

A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasis

2024-04-11

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> In a recent Phase IIa clinical trial, the candidate leishmaniasis vaccine ChAd63-KH was shown to be safe and immunogenic in Sudanese patients with post kala-azar dermal leishmaniasis (PKDL). However, its value as a stand-alone therapeutic was unknown. <h4>Methods</h4> To assess the therapeutic efficacy of ChAd63-KH, we conducted a “window of opportunity” randomized, double-b...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
66fb9ba7-a6db-5962-804c-6c8c5034e273
DOI
10.1101/2024.04.11.24305597
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A randomized double-blind Phase IIb trial to evaluate the efficacy of ChAd63-KH for the treatment of post kala-azar dermal leishmaniasisDOI 10.1101/2024.04.11.24305597
Select a neighboring publication to make it the new centre.